DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Impact of CYP2C19*17 on the Pharmacokinetics of Proguanil and Clopidogrel

Information source: University of Southern Denmark
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: CYP2C19 Genotypes

Intervention: Proguanil (Drug); Clopidogrel (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: University of Southern Denmark

Summary

The aim of this study is to investigate if the genetic variant CYP2C19*17 affects the pharmacokinetics of proguanil and clopidogrel.

Clinical Details

Official title: Impact of CYP2C19*17 on the Pharmacokinetics of Proguanil and Clopidogrel

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome: Proguanil pharmacokinetics. Primary endpoint is cycloguanil formation clearance.

Secondary outcome: Pharmacokinetics of the derivatised active clopidogrel metabolite.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Healthy volunteers

- Written consent

- Age 18-65

- CYP2C19*1 and or CYP2C19*17 genotype.

Exclusion Criteria:

- Daily medication

- Alcohol abuse

- Pregnancy

- Breastfeeding

Locations and Contacts

Clinical Pharmacology, University of Southern Denmark, Odense, Fyn DK-5000, Denmark
Additional Information

Starting date: October 2011
Last updated: July 2, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017